Targets › DARS
1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 4; Infectious disease; next expected readout Jun 2027.
Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. (UniProt, P14868)
Open in Phaseline: the race on DARS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MicuRx | Contezolid Bacterial 70S ribosome inhibitor | DARS | Phase 3 | Diabetic Foot Infection; Mycobacterium Avium Complex Pulmonary Disease; Pulmonary Tuberculosis | Jun 2027 |
Mycobacterium Avium Complex Pulmonary Disease (2) Diabetic Foot Infection (1) Pulmonary Tuberculosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.